Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18279560 | 0.85 | ALDH1A1 (0.39) | FNTAFNTBGRIK1ALDH1A1 | |
| SCHEMBL18279562 | 0.85 | ALDH1A1 (0.39) | FNTAFNTBGRIK1ALDH1A1 | |
| SCHEMBL15570359 | 0.78 | FNTA (0.42) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL15570361 | 0.78 | FNTA (0.42) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL1333037 | 0.75 | FNTA (0.46) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL1333039 | 0.75 | FNTA (0.46) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL6520540 | 0.75 | FNTA (0.46) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL12045514 | 0.75 | FNTA (0.46) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| SCHEMBL6520551 | 0.75 | FNTA (0.46) | FNTAFNTBTHRBPGGT1BGRIK1 | |
| Water SCHEMBL19307710 | 0.73 | FNTA (0.45) | FNTAFNTBTHRBPGGT1BGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | BANNER LIFE SCIENCES LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210220317-A1 | FUMARATE ESTER DOSAGE FORMS WITH ENHANCED GASTROINTESTINAL TOLERABILITY | BANNER LIFE SCIENCES LLC | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220317-A1 | FUMARATE ESTER DOSAGE FORMS WITH ENHANCED GASTROINTESTINAL TOLERABILITY | FH, SI, FAH | FNTA 271/4885FNTB 675/4885THRB 3878/4885 |
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | FH, SI, FAH | FNTA 271/4885FNTB 675/4885THRB 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.